Multidrug Resistance Protein 2-Mediated Estradiol-17β-d-glucuronide Transport Potentiation: In Vitro-in Vivo Correlation and Species Specificity
Authors:
- H. GlavinasHGH. Glavinas
- E. KisEKE. Kis
- D. MéhnDMD. Méhn
- G. BáthoriGBG. Báthori
- Z. VeresZVZ. Veres
- L. KóboriLKL. Kóbori
- O. von RichterORO. von Richter
- K. JemnitzKJK. Jemnitz
- P. KrajcsiPKP. Krajcsi
- 1 April 2009
- journal article
- research article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 37 (4) , 794-801
Abstract
Multidrug-resistant protein 2 (MRP2/ABCC2), expressed on the canalicular membrane of hepatocytes, mediates the secretion of conjugated or nonconjugated compounds into bile and plays an important role in physiology and drug elimination. A heterocyclic compound, BPCPU [1-(1-(4-bromophenyl)-3-carbamoyl-1H-pyrazol-4-yl) urea], which was metabolically stable in vitro in rat liver microsomes and freshly isolated rat hepatocytes, demonstrated a saturable nonlinear pharmacokinetic profile in the rat. Polarized efflux was observed for this compound in Caco-2 cells, with a low Km = 1.06 ± 0.06 μM. The Caco-2 efflux was dose-dependent and saturable. Coadministration of 25 μM MK571 ([3-[[3-[2-(7-chloroquinolin-2-yl)vinyl]phenyl]-(2-dimethylcarbamoylethylsulfanyl)methylsulfanyl] propionic acid]), an MRP inhibitor, blocked the polarized efflux in Caco-2 cells. In contrast, this compound did not inhibit calcein efflux in MRP2 gene-transfected Madin-Darby canine kidney cells, suggesting that it is a substrate, not an inhibitor, of the MRP2/ABCC2 transporter. To investigate the mechanism for the nonlinear pharmacokinetics, bile duct-cannulated rats were used to obtain time profiles of plasma concentration, biliary, and urinary excretion after intravenous administration at various doses. The plasma clearance increased remarkably with decreased dose, from 1.5 ml/min/kg at 5 mg/kg to 14.9 ml/min/kg at 0.05 mg/kg. A dose-dependent biliary excretion also was observed. The results revealed that saturation of hepatobiliary secretion played a role in the dose-dependent changes in total body clearance and biliary clearance. Saturating concentrations of the Mrp2/Abcc2 substrate, BPCPU, causing decreased hepatobiliary clearance could be the major cause for the nonlinear pharmacokinetics observed in rats.Keywords
This publication has 37 references indexed in Scilit:
- Functional Analysis of Mouse and Monkey Multidrug Resistance-Associated Protein 2 (Mrp2)Drug Metabolism and Disposition, 2006
- Mice lacking Mrp3 (Abcc3) have normal bile salt transport, but altered hepatic transport of endogenous glucuronidesJournal of Hepatology, 2006
- On the putative co‐transport of drugs by multidrug resistance proteinsFEBS Letters, 2005
- MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecidInternational Journal of Cancer, 2005
- ESTRADIOL 3-GLUCURONIDE IS TRANSPORTED BY THE MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2 BUT DOES NOT ACTIVATE THE ALLOSTERIC SITE BOUND BY ESTRADIOL 17-GLUCURONIDEDrug Metabolism and Disposition, 2004
- Differential Modulation of the Human Liver Conjugate Transporters MRP2 and MRP3 by Bile Acids and Organic AnionsJournal of Biological Chemistry, 2003
- Function of Uptake Transporters for Taurocholate and Estradiol 17β-D-Glucuronide in Cryopreserved Human HepatocytesDrug Metabolism and Pharmacokinetics, 2003
- Characterization of Methotrexate Transport and Its Drug Interactions with Human Organic Anion TransportersThe Journal of Pharmacology and Experimental Therapeutics, 2002
- A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndromeHepatology, 1997
- cDNA Cloning of the Hepatocyte Canalicular Isoform of the Multidrug Resistance Protein, cMrp, Reveals a Novel Conjugate Export Pump Deficient in Hyperbilirubinemic Mutant RatsJournal of Biological Chemistry, 1996